LRRK2
Leucine-Rich Repeat Kinase 2 (Dardarin / PARK8)
ロイシンリッチリピートキナーゼ2（LRRK2 / PARK8遺伝子）
1. Biological & Technical Mechanism
LRRK2 encodes a large 2,527-amino-acid protein containing both a Roc-COR GTPase domain and a serine/threonine kinase domain. Pathogenic variants (most notably G2019S and R1441C/G) hyperactivate LRRK2 kinase activity, leading to hyperphosphorylation of Rab GTPase substrates (Rab8A, Rab10, Rab29), impaired ciliogenesis in striatal cholinergic interneurons, and defective lysosomal homeostasis.
LRRK2はGTPaseドメインとセリン/スレオニンキナーゼドメインを併せ持つ大型タンパク質をコードします。G2019S変異やR1441C/G変異などの病的バリアントはLRRK2のキナーゼ活性を異常亢進させ、細胞内小胞輸送を担うRabファミリーGTPase（Rab8A, Rab10等）の過剰リン酸化、リソソーム・オートファジー系の機能不全、および線条体コリン作動性介在ニューロンの一次繊毛形成障害を引き起こします。
2. Open Science & Clinical Trial Significance
Because LRRK2 kinase hyperactivation is also observed in a subset of idiopathic Parkinson's disease patients, small-molecule LRRK2 kinase inhibitors and ASOs are leading candidates in the Michael J. Fox Foundation (MJFF) therapeutic pipeline.
遺伝子変異を持たない孤発性パーキンソン病の一部でもLRRK2経路の活性化が確認されているため、LRRK2低分子キナーゼ阻害薬およびアンチセンス核酸医薬はMJFF（マイケル・J・フォックス財団）等が支援する創薬パイプラインの最重要クラスの一つです。
Related Neuroscience Terms & Standards
Presynaptic neuronal protein encoded by SNCA whose misfolding and fibrillar aggregation form Lewy bodies in Parkinson's disease and Lewy body dementia.
Comprehensive four-part clinical rating scale quantifying non-motor experiences, activities of daily living, motor examination (Part III), and motor complications in Parkinson's disease.
High-throughput transcriptomic profiling at individual cell or nucleus resolution, enabling identification of disease-associated microglia (DAM), astrocytes, and vulnerable neuronal subtypes.
Open Datasets & Research Publications Related to LRRK2
Peripheral immunoinflammatory markers and clinical correlations in Parkinson's disease patients carrying LRRK2 G2385R and R1628P variants
Peripheral inflammation in Parkinsons disease (PD) remains poorly characterised among carriers of Asian-prevalent LRRK2 G2385R and R1628P variants. We investigated plasma immunoinflammatory markers (i.e., IL-6, TNF-, CCL2, CX3CL1, CCL5, and VCAM-1) via multiplex immunoassay in 240 participants: PD-G...
Cumulative and Interactive Effects of Heavy Metal Mixtures Across Neurodegenerative Diseases: A Comparative Review of Alzheimer, Parkinson, Amyotrophic Lateral Sclerosis and Multiple Sclerosis.
Heavy metals and metalloids are persistent environmental contaminants that accumulate in the central nervous system and interact with endogenous essential metals, yet most neurotoxicological research continues to treat metals as independent agents rather than as co-occurring mixtures. This review systematically compares the evidence for cumulative and interactive effects of heavy metal mixtures across four major neurodegenerative diseases-Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS)-asking which metal combinations have been directly documented for each disease, and whether these patterns are disease-specific or shared. Following a PubMed search (January 2016-June 2026), 93 unique studies were included (AD: 49; PD: 38; ALS: 19; MS: 18; 31 shared across diseases). Combined exposure to lead, cadmium, arsenic, and mercury is linked to amyloid-beta accumulation and dementia risk in AD; manganese-vanadium co-exposure produces more severe dopaminergic damage in PD than either metal alone, with manganese activating the familial PD gene LRRK2; a multi-metal mixture in ALS was associated with a three-fold higher disease risk independent of genetic susceptibility; and MS showed almost no designed mixture studies despite considerable single-metal data, with conflicting findings across cohorts. Three general mechanisms were identified: competition at shared membrane transporters (notably DMT1), sequestration by metal-binding proteins, and direct synergistic or antagonistic interactions, in which essential elements can modulate toxic-metal handling. Mixture-statistics approaches (WQS, BKMR), already established for AD and PD, should be extended to MS to close this evidence gap.
Dandiset 000026: Subthalamic Nucleus Local Field Potentials (LFP) and Beta-Band Dynamics in Parkinson’s Patients
High-density intraoperative and chronically implanted deep brain stimulation (DBS) electrode recordings during motor resting and movement states from 34 patients with idiopathic PD.
OpenNeuro ds003505: Dopaminergic Striato-Cortical Circuit Connectivity in Parkinson’s Disease during Motor Execution
This open-access 3T fMRI dataset evaluates striato-cortical circuit connectivity across 72 Parkinsonian patients and controls under levodopa ON vs. OFF states. Complete with behavioral logs, it offers foundational data for modeling dopaminergic network dynamics in motor execution.
Pharmacological Inhibition of mTORC1 Reduces Neural Death and Damage Volume After MCAO by Modulating Microglial Reactivity
Preclinical evaluation of novel mTORC1 inhibitors in neurodegenerative models demonstrating reduced neuroinflammation.
Continuous High-Frequency Smartwatch Sensor Telemetry Predicts Parkinson’s Motor Fluctuation Subtypes
A 24-month longitudinal cohort of 650 Parkinson’s patients monitored with wrist-worn IMU accelerometer arrays establishes automated machine learning scores correlating with MDS-UPDRS Part III subscores.
Disclaimer: This encyclopedia entry is intended for academic neuroscience research and data science reference only, and does not constitute medical advice.